Modified Antibody Market Poised USD 7.36 Billion by 2035, Driven by Personalized Medicine and Biopharmaceutical Research
The global modified antibody market size is valued at USD 3.10 billion in 2025 and is predicted to hit around USD 7.36 billion by 2035, rising at a 9.04% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
Ottawa, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The global modified antibody market size is calculated at USD 3.38 billion in 2026 and is expected to reach around USD 7.36 billion by 2035, growing at a CAGR of 9.04% for the forecasted period. The growth of the market is driven by the growth of personalised medicine and biopharmaceutical research.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6320
Key Takeaways
- North America dominated the market by capturing 40% revenue share in 2024.
- Asia Pacific is expected to grow fastest during the forecast period.
- By type of modification, the bispecific antibodies segment led with a 35% revenue share of the modified antibody market in 2024.
- By type of modification, the Fc-engineered antibodies segment is expected to be the fastest-growing in the studied years.
- By therapeutic area, the oncology segment held a major share of 50% of the market in 2024.
- By therapeutic area, the autoimmune diseases segment is expected to grow at the fastest CAGR during 2025-2034.
- By end-user, the pharmaceutical and biotechnology companies segment registered dominance with a 60% share of the market in 2024.
- By end-user, the contract research organisations (CROs) segment is expected to grow rapidly in the coming years.
Market Overview & Potential
The modified antibody market encompasses the development, production, and commercialisation of antibodies that have been engineered or modified to enhance their specificity, affinity, stability, or therapeutic efficacy. These modifications can include alterations to the antibody's structure, such as glycosylation changes, bispecific configurations, or the incorporation of payloads for targeted drug delivery. Modified antibodies are pivotal in various therapeutic areas including oncology, autoimmune diseases, and infectious diseases, offering improved treatment outcomes compared to conventional antibodies.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What is the Growth Potential Responsible for The Growth of The Modified Antibody Market?
The modified antibody market is driven by the increasing demand for personalised medicine and targeted therapies, fueled by significant research and development (R&D) investments. Key drivers include advancements in antibody engineering, such as the development of new formats like bispecific antibodies and antibody fragments, which offer more precise and versatile therapeutic approaches. Additionally, the growing prevalence of chronic diseases like cancer and infectious diseases, along with a rising number of clinical trials and the launch of new biotech products, is further expanding the market.
What Are the Growing Trends Associated with the Modified Antibody Market?
- Integration of technology: AI and machine learning are being integrated into the antibody discovery process to improve target specificity and shorten development times.
- Shift in delivery method: There is a growing trend towards subcutaneous delivery, which is expanding at a significant CAGR and challenging the traditional intravenous route.
- Increased R&D investment: A large portion of biopharmaceutical research funding is being allocated to antibody-related development, including clinical trials and next-generation formats.
- Focus on manufacturing: High-yield cell line engineering and advancements like high-density bioreactors are improving production efficiency and scalability.
-
Rise of advanced formats: Bispecific antibodies and antibody-drug conjugates (ADCs) are seeing significant growth, improving therapeutic effectiveness by targeting cancer cells more precisely and with fewer side effects.
What Is the Growing Challenge in the Modified Antibody Market?
The modified antibody market faces challenges in production scale-up and cost, product stability, and complex regulatory hurdles. Additionally, technical issues in development, such as achieving the desired efficacy with potent payloads in antibody-drug conjugates (ADCs) and consistently monitoring product quality, present significant obstacles.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Regional Analysis
How Did North America Dominate the Modified Antibody Market in 2024?
North America dominated the market by capturing 40% revenue share in 2024. The North American modified antibody market is a significant and growing sector. This growth is driven by factors such as strong R&D infrastructure, advanced healthcare systems, and a high prevalence of diseases like cancer and autoimmune disorders. The market is expected to continue its expansion, driven by strong demand for custom antibodies and the therapeutic applications of monoclonal antibodies.
What Made the Asia Pacific Significantly Grow in The Modified Antibody Market In 2024?
Asia Pacific is expected to grow fastest during the forecast period. The modified antibody market in the Asia Pacific is growing rapidly, projected to expand significantly in the coming years, particularly in the recombinant and monoclonal antibody sectors. Key drivers include rising investment in R&D, a high cancer burden, and increased government funding for biotechnology and pharmaceuticals. China is currently the largest market, but India is expected to see the highest growth rate.
Segmental Insights
By type of modification,
The bispecific antibodies segment led with a 35% revenue share of the modified antibody market in 2024. Bispecific antibodies are engineered to bind two different antigens or two different epitopes simultaneously, allowing them to target cancer cells more precisely while activating immune responses. These antibodies are increasingly used in oncology, especially in haematological malignancies and solid tumours, because they improve tumour cell recognition and immune cell recruitment. Rapid advancements in protein engineering platforms and increasing clinical trial approvals are driving strong market growth for this segment.
The Fc-engineered antibodies segment is expected to be the fastest-growing in the studied years. Fc-engineered antibodies involve modifications to the Fc region to enhance immune system interactions, improve half-life, or modulate effector functions like antibody-dependent cell-mediated cytotoxicity (ADCC). This modification helps improve drug efficacy, safety, and dosing frequency. Rising demand for long-lasting and more potent antibody therapies is boosting the adoption of Fc-engineered antibodies across therapeutic pipelines.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
By therapeutic area,
The oncology segment held a major share of 50% of the market in 2024. Oncology represents the largest and most rapidly growing therapeutic segment for modified antibodies, driven by the global rise in cancer prevalence and increasing focus on targeted therapies. Strong investments in cancer biologics research, favourable regulatory support, and an increasing number of antibody-based drug approvals are accelerating the expansion of this segment worldwide.
The autoimmune diseases segment is expected to grow at the fastest CAGR during 2025-2034. In autoimmune diseases, modified antibodies are used to selectively target overactive immune components without broadly suppressing the immune system. The ability of modified antibodies to offer higher specificity and reduced side effects compared to traditional immunosuppressants is increasing their clinical adoption. The growing prevalence of autoimmune disorders and rising healthcare awareness are supporting steady growth in this segment.
By end-user,
The pharmaceutical and biotechnology companies segment registered dominance with a 60% share of the market in 2024. Pharmaceutical and biotechnology companies are the primary end users of modified antibodies as they lead drug discovery, development, and commercialisation processes. The increasing focus on personalised medicine and biologics-based therapies continues to strengthen demand for modified antibody technologies among large and mid-sized biopharma companies.
The contract research organisations (CROs) segment is expected to grow rapidly in the coming years. Contract Research Organisations play an important role by providing antibody development services such as antibody modification, preclinical testing, and clinical trial management. The growth of the modified antibody market is strongly supported by the expansion of CRO capabilities, rising R&D outsourcing trends, and increasing complexity of biologics development pipelines.
Browse More Insights of Towards Healthcare:
The global bispecific antibody market was valued at USD 11.97 billion in 2024, increased to USD 17.24 billion in 2025, and is projected to surge to approximately USD 460.23 billion by 2034, expanding at a remarkable CAGR of 44.04% from 2025 to 2034.
The global complement C4 antibody market reached USD 19.21 billion in 2023 and is expected to grow to USD 68.48 billion by 2034, registering a CAGR of 12.25% between 2024 and 2034.
The monoclonal antibody discovery platform market is rapidly evolving worldwide, with revenues anticipated to reach several hundred million dollars between 2025 and 2034.
The global epigenetic antibodies market stood at USD 2.29 billion in 2024, rose to USD 2.7 billion in 2025, and is forecast to reach USD 12.01 billion by 2034, growing at a CAGR of 18.04% during 2025–2034.
The global antibody optimization service market was valued at USD 2.77 billion in 2024, grew to USD 3 billion in 2025, and is projected to reach USD 6.07 billion by 2034, reflecting a CAGR of 8.45% from 2025 to 2034.
The global antibody discovery market was valued at USD 8.31 billion in 2024, increased to USD 9.1 billion in 2025, and is expected to reach USD 20.71 billion by 2034, expanding at a CAGR of 9.54% over the forecast period.
The global antibody therapy market size was USD 278.25 billion in 2024, grew to USD 314.64 billion in 2025, and is projected to reach USD 951.24 billion by 2034, registering a CAGR of 13.08% between 2025 and 2034.
The next-generation bispecific antibody market is also accelerating globally, with projected revenues reaching several hundred million dollars between 2025 and 2034.
The U.S. bispecific antibody market was valued at USD 11.2 billion in 2025, increased to USD 16.19 billion in 2026, and is forecast to reach USD 448.62 billion by 2035, growing at a CAGR of 44.52% during 2026–2035.
The global human combinatorial antibody libraries market was estimated at USD 116.2 million in 2024, rose to USD 122 million in 2025, and is projected to reach USD 189.57 million by 2034, recording a CAGR of 5.04% between 2025 and 2034.
Recent Developments
- In October 2025, Jade Biosciences, Inc., a clinical-stage biotechnology company, launched JADE201, its investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R).
- In August 2025, Swedish BioArctic AB’s partner Eisai Pharma introduced the European launch of their Alzheimer’s antibody lecanemab in Austria, which will be followed by the German launch on September 1, 2025.
Modified Antibody Market Key Players List
- Pfizer Inc.
- Sanofi
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- Genmab A/S
- Bristol Myers Squibb
- AstraZeneca plc
- GlaxoSmithKline plc (GSK)
- Bayer AG
- Seagen Inc.
- Biogen Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
Segments Covered in The Report
By Type of Modification
- Bispecific Antibodies
- Antibody-Drug Conjugates (ADCs)
- Glycoengineered Antibodies
- Fc-Engineered Antibodies
- Other Modifications
By Therapeutic Area
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Disorders
- Other Diseases
By End-User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutions
- Contract Research Organisations (CROs)
- Others
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6320
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
